作者
Jordi Izquierdo-Serra,Rubén Martín,Aina Moll‐Udina,Carolina Bernal-Morales,Gonzaga Garay‐Aramburu,Jorge Sánchez‐Monroy,Carolina Arruabarrena,Ana Fernández-Hortelano,Marta S. Figueroa,Maximino Abraldes,Francisco Javier Lavid de los Mozos,Miguel Ángel Zapata,José M. Ruiz‐Moreno,Laura Broc-Iturralde,Juan Jacobo González Guijarro,Jose Juan Escobar-Barranco,Roberto Gallego‐Pinazo,Alba Parrado‐Carrillo,Marina Dotti‐Boada,Socorro Alforja,Marc Figueras‐Roca,Daniel Barthelmes,Mark C. Gillies,Ricardo P. Casaroli‐Marano,Javier Zarranz‐Ventura,Javier Zarranz‐Ventura,Alba Parrado‐Carrillo,Marc Figueras‐Roca,Aina Moll‐Udina,Jordi Izquierdo-Serra,Alba Serrano,Jose Grau,Carolina Bernal-Morales,Socorro Alforja,Ricardo P. Casaroli‐Marano,Laura Sararols-Ramsay,Gabriel Londoño,Maximiliano Olivera,Karim Bañon,Cynthia Rethati,Pilar Calvo,Jorge Sánchez,Martín Puzo,Óscar Ruiz‐Moreno,Gonzaga Garay‐Aramburu,A Larrauri-Arana,Ángela Gómez-Moreno,David Rodríguez-Feijoo,Enrique Diaz-de-durana-Santa-coloma,Maialen Aldazabal-Echeveste,Zuriñe del-Barrio-Lopez-de-Ipiña,Irene Herrero-Díaz,José García‐Arumí,Helena Brosa Morros,Laura Sánchez-Vela,Miguel Ángel Zapata,Carolina Arruabarrena,R. Milner,F. de Aragón,Maximino José Abraldes López-Veiga,María Lidia Gómez Conde,María José Rodríguez‐Cid,María Isabel Fernández Rodríguez,Pablo Varela,Ana Fernández-Hortelano,J. Zarallo-Gallardo,Rosario Cobo-Soriano,Inmaculada Lozano-Escobar,Paula Moreno-Martín,José M. Ruiz‐Moreno,Rocío Vega-González,María García Zamora,Ignacio Flores‐Moreno,Xavier Valldeperas,Laura Broc-Iturralde,F. Vilaplana Mira,Sandra Gómez Sánchez,Pamela Campos Figueroa,Jose Juan Escobar-Barranco,Manel Fernández-Bonet,Begoña Pina-Marín,Eva Salinas Martínez,Jaime Guijarro,Muxima Acebes García,Sonia Aparicio Sanchís,Jonathan Cacelliere Fernández,Marta Belmonte Grau,Francisco Javier Ascaso Puyuelo,Ana Honrubia Grijalbo,Ana Boned Murillo,María Dolores Díaz,Guillermo Pérez Rivasés,Ismael Bakkali El Bakkali,Roberto Gallego‐Pinazo,Marta Cholbi,Rosa Dolz‐Marco,Marta S. Figueroa,E. Ciancas,Dhananjay Raje,Cesar Azrak Haskour,Alvaro Piñero Sánchez,Nelida Sanz,Ester Carreño,Nestor Ventura,Pablo Carnota-Méndez,Carlos Méndez-Vázquez,Carlos Torres-Borrego,Daniel Velázquez-Villoria,Alfredo García‐Layana,Manuel Sáenz de Viteri,Elena Alonso,Luis J. Castillón Torre,Pablo Catalán Muñoz,María Eugenia Tena Sempere,María de Fátima Álvarez Gil,Purificación Piñas García,María Eugenia Mantrana Bermejo,Francisco Javier Lavid de los Mozos,M. Asencio Durán,Luís Arias,Estefanía Cobos Martín,Daniel Lorenzo Parra,Marta Rodríguez-Núñez,Ana Campo Gesto,Jesús Pareja Esteban,María del Pilar Ruiz del Tiempo,Enrique Rodríguez de la Rúa,M.Á. Espiñeira-Periñán,Magdalena Sotomayor Toribio
摘要
To evaluate the influence of macular neovascularization (MNV) lesion type on 12-month clinical outcomes in treatment-naive eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF drugs nationwide. Multicenter national nAMD database observational study. One thousand six hundred six treatment-naive nAMD eyes (1330 patients) undergoing anti-VEGF therapy for 12 months nationwide. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution letters, number of injections and visits were was collected using a validated web-based tool. Neovascular lesion phenotype was classified as type 1 (T1, n = 711), type 2 (T2, n = 505), type 3 (T3, n = 315), and aneurysmal type 1 (A-T1, n = 75), according to the new proposed consensus classification. Mean VA change at 12 months, final VA at 12 months, number of injections, time to lesion inactivation. A total of 1606 treatment-naive nAMD eyes (1330 patients) received a median of 7 injections over 12 months. Mean (± standard deviation) baseline VA was significantly lower for T2 (49.4 ± 23.5 letters) compared with T1 (57.8 ± 20.8) and T3 (58.2 ± 19.4) (both P < 0.05) lesions. Mean VA change at 12 months was significantly greater for A-T1 (+9.5 letters) compared with T3 (+3.1 letters, P < 0.05). Patients with T3 lesions had fewer active visits (24.9%) than those with other lesion types (T1, 30.5%; T2, 32.6%; A-T1, 27.5%; all P < 0.05). Aflibercept was the most used drug in A-T1 lesions (70.1%) and ranibizumab in T1 (40.7%), T2 (57.7%), and T3 (47.6%) lesions. This study highlights the relevance of MNV type on clinical outcomes in nAMD and reports significant differences in baseline VA, VA change, and lesion activity at 12 months. This report provides data about lesion-specific clinical features, which may guide the management of nAMD cases and potentially support personalized clinical decision making for these patients. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.